Optimization of a coagulation factor VIIa inhibitor found in factor Xa inhibitor library

Bioorganic and Medicinal Chemistry

Volumn 13, Issue 5, 2005, Pages 1487-1496

  Sagi, Kazuyuki ^a   Fujita, Koichi ^a   Sugiki, Masayuki ^a   Takahashi, Mitsuo ^a   Takehana, Shunji ^a   Tashiro, Kazumi ^a   Kayahara, Takashi ^a   Yamanashi, Masahiro ^a   Fukuda, Yumiko ^a   Oono, Seiji ^a   Okajima, Akiko ^a   Iwata, Seinosuke ^a   Shoji, Masataka ^a   Sakurai, Kuniya ^a  

^a AJINOMOTO CO INC   (Japan)

Author keywords

Factor VIIa; Inhibitor

Indexed keywords

3 [4 AMIDINO 2 [2 (2 AMINOBENZOTHIAZOLE 6 CARBONYL)AMINOETHOXY]PHENYL] 2 OXOPROPIONIC ACID BISTRIFLUOROACETATE; 3 [4 AMIDINO 2 [2 (2 AMINOQUINOLINE 6 CARBONYL)AMINOETHOXY]PHENYL] 2 OXOPROPIONIC ACID BISTRIFLUOROACETATE; 3 [4 AMIDINO 2 [2 (4 AMIDINOBENZOYLAMINO)ETHOXY]PHENYL] 2 OXOPROPIONIC ACID BISTRIFLUOROACETATE; 4 BENZOYLAMINO 5 [5 AMIDINO 2 (2 CARBOXY 2 OXOETHYL)PHENOXY]PENTANOIC ACID TRIFLUOROACETATE; 4 [(2 AMINOBENZIMIDAZOLE 5 CARBONYL)AMINO] 5 [5 AMIDINO 2 (2 CARBOXY 2 OXOETHYL)PHENOXY]PENTANOIC ACID BISTRIFLUOROACETATE; 4 [(2 AMINOBENZOTHIAZOLE 6 CARBONYL)AMINO] 5 [5 AMIDINO 2 (2 CARBOXY 2 OXOETHYL)PHENOXY]PENTANOIC ACID BISTRIFLUOROACETATE; 4 [(2 AMINOQUINOLINE 6 CARBONYL)AMINO] 5 [5 AMIDINO 2 (2 CARBOXY 2 OXOETHYL)PHENOXY]PENTANOIC ACID BISTRIFLUOROACETATE; 4 [(2 METHYLBENZIMIDAZOLE 5 CARBONYL)AMINO] 5 [5 AMIDINO 2 (2 CARBOXY 2 OXOETHYL)PHENOXY]PENTANOIC ACID BISTRIFLUOROACETATE; 4 [(4 GUANIDINO 3 METHYLBENZOYL)AMINO] 5 [5 AMIDINO 2 (2 CARBOXY 2 OXOETHYL)PHENOXY]PENTANOIC ACID BISTRIFLUOROACETATE; 4 [(4 GUANIDINOBENZOYL)AMINO] 5 [5 AMIDINO 2 (2 CARBOXY 2 OXOETHYL)PHENOXY]PENTANOIC ACID BISTRIFLUOROACETATE; 4 [(BENZIMIDAZOLE 5 CARBONYL)AMINO] 5 [5 AMIDINO 2 (2 CARBOXY 2 OXOETHYL)PHENOXY]PENTANOIC ACID BISTRIFLUOROACETATE; 4 [[4 (1 METHYLGUANIDINO)BENZOYL]AMINO] 5 [5 AMIDINO 2 (2 CARBOXY 2 OXOETHYL)PHENOXY]PENTANOIC ACID BISTRIFLUOROACETATE; BLOOD CLOTTING FACTOR 10A INHIBITOR; BLOOD CLOTTING FACTOR 7A INHIBITOR; THROMBOPLASTIN; UNCLASSIFIED DRUG;

ARTICLE; BINDING SITE; BLOOD CLOTTING TIME; CONCENTRATION (PARAMETERS); HUMAN; NONHUMAN; NORMAL HUMAN;

EID: 13444256329     PISSN: 09680896     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bmc.2004.12.033     Document Type: Article

References (23)

1. Parts of this work have already been presented in the following publication: Sugiki, M.; Sagi, K.; Fujita, K.; Kayahara, T.; Takehana, S.; Sakurai, K.; Tashiro, K. PCT Int. Appl. WO 0142199, 2001
2. L.C. Petersen, S. Valentin, and U. Hender Thromb. Res. 79 1995 1 47
3. Much effort has been focused on thrombin or fXa inhibitors: C.A. Coburn Exp. Opin. Ther. Pat. 11 5 2001 721 738
4. A. Betz Exp. Opin. Ther. Pat. 11 6 2001 1007
5. B.J. Biemond, M. Levi, H. Ten Cate, H.R. Soule, L.D. Morris, and D.L. Foster Thromb. Haemost. 73 1995 223
6. B. Arnljots, M. Ezban, and U. Hedner J. Vasc. Surg. 25 1997 341
7. M.S. Bajaj, and S.P. Bajaj Thromb. Haemost. 78 1997 471
8. L.A. Robinson, and M.K. Saiah Annu. Rep. Med. Chem. 37 2002 85 94
9. J.J. Parlow, B.L. Case, T.A. Dice, R.L. Fenton, M.J. Hayes, D.E. Jones, W.L. Neumann, R.S. Wood, R.M. Lachance, T.J. Girard, N.S. Nicholson, M. Clare, R.A. Stegeman, A.M. Stevens, W.C. Stallings, R.G. Kurumbail, and M.S. South J. Med. Chem. 46 19 2003 4050 4062
10. O. Klingler, H. Matter, M. Schudoku, S.P. Bajaj, J. Czech, M. Lorenz, H.P. Nestler, H. Schreuder, and P. Wildgoose Bioorg. Med. Chem. Lett. 13 2003 1463 1467
11. W.B. Young, A. Kolesnikov, R. Rai, P.A. Sprengeler, E.M. Leahy, W.D. Shrader, J. Sangalang, J. Burgess-Henry, J. Spencer, K. Elrod, and L. Cregar Bioorg. Med. Chem. Lett. 11 2001 2253 2256
12. J.T. Kohrt, K.J. Filipski, S.T. Rapundalo, W.L. Cody, and J.J. Edmunds Tetrahedron Lett. 41 2000 6041 6044
13. D.W. Banner, A. D'Arcy, C. Chene, F.K. Winkler, A. Guha, W.H. Konigsberg, Y. Nemerson, and D. Kirchhofer Nature 380 1996 41
14. K. Sagi, T. Nakagawa, M. Yamanashi, S. Makino, M. Takahashi, M. Takayanagi, K. Takenaka, N. Suzuki, S. Oono, N. Kataoka, K. Ishikawa, S. Shima, Y. Fukuda, T. Kayahara, S. Takehana, Y. Shima, K. Tashiro, H. Yamamoto, R. Yoshimoto, S. Iwata, T. Tsuji, K. Sakurai, and M. Shoji J. Med. Chem. 46 10 2003 1845 1857
15. Residues are numbered with chymotrypsin-based numbering: W. Bode, I. Mayr, U. Baumann, R. Huber, S.R. Stone, and J. Hofsteenge EMBO J. 8 11 1989 3467 3475
16. In our study on fXa inhibitors, the crystal structure of an 2-substituted APPA-trypsin complex shows that although the bonding linkage is formed between the pyruvic acid moiety and the Ser 195, the overall docking mode including the pyruvic acid is still similar to that of the calculated noncovalent 2-substituted APPA-fXa complex. Therefore we consider the overall docking mode of 1a will be similar to the noncovalently calculated binding mode: Takahashi, M.; Sagi, K.; Yamanashi, M.; Makino, S.; Suzuki, N.; Takayanagi, M.; Nakagawa, T.; Ishikawa, K.; Shoji, M. 13th European Symposium on Quantitative Structure-Activity Relationships, Düsseldorf, August 2000
17. M. Marquart, J. Walter, J. Deisenhofer, W. Bode, and R. Huber Acta Crystallogr. B39 1983 480 490
18. a values described in this paper were taken from Dictionary of Organic Compounds on CD-ROM version 10:2 Chapman & Hall, or H. Yamanaka, T. Hino, M. Nakagawa, and T. Sakamoto Chemistry of Heterocyclic Compounds 1988 Kodansha Scientific Japan 4-06-190754-9
19. There are very few publications that address therapeutic index (efficacy/bleeding) for a small-molecule inhibitor of TF/fVIIa: O.D. Suleymanov, J.A. Szalony, A.K. Salyers, R.M. Lachance, J.J. Parlow, M.S. South, R.S. Wood, and N.S. Nicholson J. Pharmacol. Exp. Ther. 306 3 2003 1115 1121
20. K. Padmanabhan, K.P. Padmanabhan, A. Tulinsky, C.H. Park, W. Bode, R. Huber, D.T. Blankenship, A.D. Cardin, and W. Kisiel J. Mol. Biol. 232 1993 947 966
21. D.W. Banner, and P. Hadvary J. Biol. Chem. 266 1992 20085 20093
22. Takahashi, M.; Shoji, M.; Makino: S. 24th Symposium on Structure-Activity Relationships, Osaka, November 1996; 13SP05
23. 50) of an enzymatic reaction Biochem. Pharmacol. 22 1973 3099 3108